Derma Sciences Inc. (Nasdaq: DSCI) terminated its Phase 3 clinical trial of aclerastide to treat diabetic foot ulcers. Shares of the tissue regeneration company plunged $1.57 to $4.03.
Derma Sciences terminates clinical trial
November 12, 2015 at 11:51 AM EST
